Car-t cell therapy for autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests a type of immune therapy called CAR-T cells to treat autoimmune diseases. The treatment targets B cells, which are part of the immune system that can attack your own body in autoimmune conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have B cells (a type of immune cell) that the treatment can target.
- You must be generally healthy and able to care for yourself (a score of 80 or higher on a standard health scale).
- Your red blood cell count (hemoglobin) must be at least 80 g/L.
- You must be able to have a blood draw (no issues with collecting blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two cell therapies—mesenchymal stem cells (which help reduce inflammation) and CAR-T cells (a type of immune cell engineered to target harmful cells)—to see if together they can better treat autoimmune diseases. It may offer a new option for people whose current treatments aren't working well.
This trial tests a special type of cell therapy (CAR-T cells) to see if it can help treat autoimmune diseases like lupus or scleroderma. If you qualify, you might get a chance to try this new approach that could help your immune system stop attacking your own body.
This trial tests a new treatment using your own immune cells, modified to target and calm the overactive immune system that causes autoimmune diseases. It may help reduce symptoms for conditions like lupus, scleroderma, and others.
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins (CD19 and CD70) on your cancer cells. It is for patients with B-cell cancers that didn't respond to previous treatments.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.